Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, affecting millions of people worldwide. AMD is characterized by degeneration of the macula, the central portion of the retina responsible for sharp, detailed vision. Current treatments for AMD require frequent injections, which are burdensome for patients and healthcare systems. Gene therapy for AMD is emerging as a promising alternative, offering the potential for long-lasting treatment with a single administration. The market for gene therapy for AMD is expanding rapidly, driven by the rising prevalence of AMD, advancements in gene therapy technologies, and the need for more convenient treatments.

According to recent market analysis, the global Gene Therapy For Age-Related Macular Degeneration Market was valued at approximately USD 1 billion in 2025 and is projected to reach USD 5 billion by 2035, growing at a CAGR of 13.1%. This growth reflects both the increasing burden of AMD and the pharmaceutical industry's investment in innovative gene therapies.

Rising Prevalence of AMD

The primary driver is the rising prevalence of AMD. AMD affects approximately 200 million people worldwide, and its incidence is increasing as the global population ages. As life expectancy rises and the proportion of older adults grows, the number of people affected by AMD is expected to increase substantially. This demographic trend is creating sustained demand for AMD treatments, including gene therapies.

Advancements in Gene Therapy Technologies

Technological innovation is also shaping the market. Advances in gene therapy, including improved vectors (e.g., adeno-associated virus), targeted delivery, and gene editing technologies (e.g., CRISPR), are enabling more effective and safer treatments. These innovations are driving clinical development and market growth.

People Also Ask

What is the market size of gene therapy for AMD?
The gene therapy for AMD market was valued at approximately USD 1 billion in 2025 and is projected to reach USD 5 billion by 2035, growing at a CAGR of 13.1%.

What are the key gene therapy approaches for AMD?
Key approaches include adeno-associated virus (AAV) vectors, CRISPR/Cas9 gene editing, RNA interference, and stem cell therapy.

Regional dynamics further shape the market. North America leads with a valuation of USD 750 million in 2024, supported by advanced healthcare infrastructure and high AMD prevalence. Europe follows closely, while Asia-Pacific is the fastest-growing region, driven by increasing healthcare investments and rising AMD prevalence.

Tags: #GeneTherapy #AMD #AgeRelatedMacularDegeneration #Ophthalmology #VisionLoss